15 October 2014
EMA/PDCO/623408/2014
Paediatric Committee (PDCO)

PDCO monthly report of opinions on paediatric investigation plans and other activities

8-10 October 2014

Opinions on paediatric investigation plans

The Paediatric Committee (PDCO) adopted opinions agreeing paediatric investigation plans (PIPs) for the following medicines:

- Cannabidiol / delta-9-tetrahydrocannabinol, from GW Pharma Ltd, for the treatment of pain;
- Inotuzumab ozogamicin, from Pfizer Ltd., for the treatment of acute lymphoblastic leukaemia;
- Pandemic live attenuated influenza virus, from MedImmune Limited, for the prevention of influenza infection;
- Naloxone (hydrochloride), from Develco Pharma GmbH, for the treatment of opioid-induced constipation;
- Human Fibrinogen / Human Thrombin, from Instituto Grifols, S.A., for the treatment of haemorrhage resulting from a surgical procedure.

The PDCO adopted an opinion on the **refusal** of a PIP, including a waiver, for Glycopyrronium bromide, from Desitin Arzneimittel GmbH, for the treatment of sialorrhoea.

A PIP sets out a programme for the development of a medicine in the paediatric population. The PIP aims to generate the necessary quality, safety and efficacy data through studies to support the authorisation of the medicine for use in children of all ages. These data have to be submitted to the European Medicines Agency, or national competent authorities, as part of an application for a marketing authorisation for a new medicine, or for one covered by a patent. In some cases, a PIP may include a waiver of the studies in one or more paediatric subsets, or a deferral.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5510
Send a question via our website www.ema.europa.eu/contact

Opinions on product-specific waivers

The PDCO adopted positive opinions for product-specific waivers, recommending that the obligation to submit data obtained through clinical studies with children be waived in all subsets of the paediatric population, for the following medicines:

- Diclofenac sodium / thiocolchicoside, from Epifarma Srl, for the treatment of musculoskeletal and connective tissue pain;
- Purified adenylate cyclase recombinant protein carrying subfragments of the early protein E7 antigen from human papillomavirus strain 16 (recombinant CyaA-HPV16E7) / purified adenylate cyclase recombinant protein carrying subfragments of the early protein E7 antigen from human papillomavirus strain 18 (recombinant CyaA-HPV18E7), from Genticel S.A., for the treatment of Human Papilloma Virus (HPV) 16 and/or 18 infection;
- Abaloparatide, from Triskel EU Services, Ltd, for the treatment of osteoporosis;
- Macrogol 3350, from MAYOLY SPINDLER, for the treatment of constipation;
- Varicella-zoster virus (live, attenuated), from Sanofi Pasteur MSD SNC, for the prevention of Varicella-Zoster-Virus reactivation;
- Amlodipine (besylate) / valsartan, from Novartis Europharm Ltd., for the treatment of hypertension.

Waivers can be issued if there is evidence that the medicine concerned is likely to be ineffective or unsafe in the paediatric population, or that the disease or condition targeted occurs only in adult populations, or that the medicine, or the performance of trials, does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

Opinions on modifications to an agreed PIP

The PDCO also adopts, every month, opinions on modifications to an agreed PIP, which can be requested by the applicant when the plan is no longer appropriate or when there are difficulties that render the plan unworkable. The PDCO adopted positive opinions, agreeing change(s), for the following products:

- Tigecycline, from Pfizer Limited, for the treatment of complicated skin and soft tissue infections and treatment of complicated intra-abdominal infections;
- Fluticasone propionate / formoterol fumarate, from Mundipharma Research Limited, for the treatment of asthma;
- Asenapine (maleate), from N.V. Organon, for the treatment of bipolar I disorder;
- L-asparaginase encapsulated in erythrocytes, from ERYTECH pharma S.A., for the treatment of acute lymphoblastic leukaemia;
- Fluticasone furoate / vilanterol, from Glaxo Group Limited, for the treatment of asthma;
- Perampanel, from Eisai Europe Limited, for the treatment of treatment-resistant epilepsies;
- Ticagrelor, from AstraZeneca AB, for the prevention of thromboembolic events;
- Belimumab, from Glaxo Group Limited, for the treatment of systemic lupus erythematosus;

- Dapagliflozin, from Bristol-Myers Squibb / AstraZeneca EEIG, for the treatment of type 2 diabetes mellitus;
- Midostaurin, from Novartis Europharm Ltd, for the treatment of acute myeloid leukaemia, treatment of malignant mastocytosis and treatment of mast cell leukaemia;
- Eculizumab, from Alexion Europe SAS, for the treatment of paroxysmal nocturnal haemoglobinuria and treatment of atypical haemolytic uraemic syndrome;
- Recombinant fusion protein consisting of human coagulation factor IX attached to the Fc domain of human IgG1 (rFIXFc), from Biogen Idec Ltd, for the treatment of hereditary factor IX deficiency;
- Lomitapide, from Aegerion Pharmaceuticals SAS, for the treatment of (heterozygous or homozygous) familial hypercholesterolaemia;
- Heterologous Human Adult Liver-derived Progenitor Cells (HHALPC), from Promethera Biosciences, for the treatment of urea cycle disorders and treatment of Crigler-Najjar syndrome.

Opinion on compliance check

The PDCO adopted a positive opinion on (full) compliance check for:

- Pneumococcal polysaccharide serotype 5 - diphtheria CRM197 conjugate / Pneumococcal polysaccharide serotype 18C - diphtheria CRM197 conjugate / Pneumococcal polysaccharide serotype 4 - diphtheria CRM197 conjugate / Pneumococcal polysaccharide serotype 7F - diphtheria CRM197 conjugate / Pneumococcal polysaccharide serotype 14 - diphtheria CRM197 conjugate / Pneumococcal polysaccharide serotype 19A - diphtheria CRM197 conjugate / Pneumococcal polysaccharide serotype 3 - diphtheria CRM197 conjugate / Pneumococcal polysaccharide serotype 6A - diphtheria CRM197 conjugate / Pneumococcal polysaccharide serotype 23F - diphtheria CRM197 conjugate / Pneumococcal polysaccharide serotype 9V - diphtheria CRM197 conjugate / Pneumococcal polysaccharide serotype 19F - diphtheria CRM197 conjugate / Pneumococcal polysaccharide serotype 6B - diphtheria CRM197 conjugate / Pneumococcal polysaccharide serotype 1 - diphtheria CRM197 conjugate, from Pfizer Limited, for the disease caused by Streptococcus pneumoniae;
- Aprepitant, from Merck Sharp & Dohme (Europe) Inc, for the prevention of nausea and vomiting;
- Inactivated Type 1 Poliovirus (Mahoney) / Purified Fimbriae Types 2 and 3 (FIM) / Purified Tetanus Toxoid / Polyribosylribitol phosphate (PRP) from Haemophilus influenzae type b as PRP-OMPC / Purified Pertussis Toxoid (PT) / Purified Filamentous Haemagglutinin (FHA) / Hepatitis B Surface Antigen, recombinant (HBsAg) / Inactivated Type 3 Poliovirus (Saukett) / Inactivated Type 2 Poliovirus (MEF-1) / Purified Pertactin (PRN) / Purified Diphteria Toxoid (V419), from Sanofi Pasteur MSD SNC, for the prevention of infectious diseases caused by Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis, poliovirus types 1, 2 and 3, against invasive disease caused by Haemophilus influenzae type b and infection caused by all known subtypes of hepatitis B virus;
- Fosaprepitant, from Merck Sharp & Dohme Ltd., for the prevention of nausea and vomiting;
- Ivabradine (hydrochloride), from Les Laboratoires Servier, for the treatment of coronary artery disease, treatment of angina pectoris and treatment of chronic heart failure;
- Sapropterin dihydrochloride, from Merck Serono Europe Ltd, for the treatment of hyperphenylalaninemia;

- Golimumab, from Janssen Biologics BV, for the treatment of chronic idiopathic arthritis (including rheumatoid arthritis, spondyloarthritis, psoriatic arthritis, and juvenile idiopathic arthritis).

A compliance check is performed to verify that all the measures agreed in a PIP and reflected in the Agency's decision have been conducted in accordance with the decision, including the agreed timelines. Full compliance with all studies/measured contained in the PIP is one of several prerequisites for obtaining the rewards and incentives provided for in Articles 36 to 38 of the Paediatric Regulation.

Before the submission of a request for a compliance check, applicants are encouraged to consult the Agency's Procedural advice for validation of a new marketing authorisation application or extension/variation application and compliance check with an agreed PIP.

Withdrawals

The PDCO noted that 5 applications were withdrawn during the late stages of the evaluation (30 days or less before completion of the procedure).

Other matters

The next meeting of the PDCO will be held on 12-14 November 2014.

– END –

Notes:

1. As of 26 January 2009, pharmaceutical companies that submit an application for a marketing authorisation for a medicinal product, or those that submit an application for an extension of indication, a new route of administration, or a new pharmaceutical form of a medicinal product already authorised in the European Union, have to provide either the results of studies in children conducted in accordance with an approved PIP, or an Agency's decision on a waiver or on a deferral.

2. PDCO opinions on PIPs and waivers are transformed into Agency's decisions within the timeframe laid down by the Paediatric Regulation (Regulation (EC) No 1901/2006, as amended). The decisions can be found on the Agency's website at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/pip_search.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d129

3. More information about the PDCO and the Paediatric Regulation is available in the Regulatory section of the Agency's website: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000023.jsp&murl=menus/regulations/regulations.jsp&mid=WC0b01ac05800240cd

4. This meeting report, together with other information on the work of the Agency's, can be found on the Agency's website: http://www.ema.europa.eu

Enquiries to: AskEMA
(http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/landing/ask_ema_landing_page.jsp&mid=)